Pharmaceuticals company Procter & Gamble Health announced Q1FY26 results Company delivered a strong performance with sales of Rs 333 crore, up 20% versus a year ago. Profit After Tax (PAT) stood at Rs 66 crore, versus Rs 17 crore a year ago. Milind Thatte, Managing Director, P&G; Health India, said: "We are pleased with the continued momentum and strong start to the FY26. These results are a reflection of our commitment towards addressing the evolving needs of our consumers and healthcare professionals, via superior brand building and go to market initiatives while improving supply chain capabilities. “Our strategy, centered on a focused portfolio of quality, trusted, and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption and an agile accountable organization, is delivering balanced and sustainable growth results. We continue to drive engagement for our consumers and healthcare professionals alike, through innovation backed by science and meaningful interventions to make life a little better every day”. Result PDF
Pharmaceuticals company Procter & Gamble Health announced Q3FY25 results Q3FY25 Financial Highlights: The third quarter reported sales of Rs 304 crore, up 23% versus the comparable period previous year PAT of Rs 61 crore, up 31% versus comparable period a year ago, owing to superior brand building activities and supported by strengthened supply chain and go-to-market capabilities. The Board of Directors has recommended a final dividend of Rs 45 per Equity Share, for the Financial Year ending March 31, 2025 Commenting on the results, Milind Thatte, Managing Director, P&G; Health India, said, “This was a period of purposeful transformation and acceleration. We invested in initiatives to address the changing needs of our consumers and healthcare professionals, while strengthening our go-to-market and supply chain capabilities. Our strategy - centered on a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure, helped us build a strong foundation for long-term growth. This integrated strategy continues to guide our efforts to generate sustainable, balanced top- and bottom-line growth, along with value creation for our consumers, customers, and shareholders alike” Result PDF
Pharmaceuticals company Procter & Gamble Health announced Q2FY25 results The Company reported sales of Rs 304 crore, flat versus a year ago. The Profit After Tax (PAT) for the quarter was Rs 91 crore, up 26% versus a year ago. Profit After Tax (PAT) was up 13% versus a year ago. The Board has declared an interim dividend of Rs 80 per equity share for the FY25. The record date for the dividend will be February 21, 2025. Milind Thatte, Managing Director, P&G; Health India, said: “This quarter was a period of strategic reinforcement as we took proactive steps to strengthen our supply network. We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure. We are confident that this strategy will enable us to meet the evolving needs of our consumers and healthcare professionals alike.” Result PDF
Pharmaceuticals company Procter & Gamble Health announced Q1FY25 results Reported sales of Rs 310 crore, change 3% compared to Q1FY24. Profit After Tax (PAT) of Rs 82 crore, change 26% compared to Q1FY24. Operational PAT is up by 8% compared to Q1FY24. Milind Thatte, Managing Director, P&G; Health India, said: “Our firstquarter results represent a sequential improvement. Our strategy, centered on a focused portfolio of quality, trusted, and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution, and value), constructive disruption and an agile accountable organization”. “We are dedicated to enhancing consumer awareness programs and strengthening our relationships with our customers and stakeholdeRs We continue to invest in initiatives that address the evolving needs of both consumers and healthcare professionals, along with strengthening our go-to-market model. We have also strengthened our reach, distribution, and retail execution, positioning us for long-term competitiveness”. Result PDF
Pharmaceuticals company Procter & Gamble Health announced Q3FY24 results: Financial Highlights: Procter & Gamble Health Limited reported a decrease in sales and profit after tax for the Q3FY24. The total sales for the quarter were Rs 248 crore compared to Rs 316 crore a year ago, marking a downturn. Correspondingly, the Profit After Tax (PAT) also declined by 21% to Rs 46 crore. For the nine-month period ending March 31, 2024, P&G; Health's sales were recorded at Rs 852 crore, which exhibited a slight reduction from the previous year's sales of Rs 913 crore. The PAT for the nine-month period stood at 184 crore, experiencing a decrease from the Rs 200 crore reported in the prior year. Milind Thatte, Managing Director, P&G; Health India, said, “The Company’s continued efforts to strengthen our reach and distribution with a transformed go-to-market model reflected in a one-time impact on the quarter’s sales owing to the transition and optimization of trade management and inventory. However, we have seen sales recover in the months of March and April. We continue to drive operational efficiency and explore innovative solutions to accelerate category growth and demand for our portfolio of trusted, quality healthcare brands. The quarter also witnessed prescription growth and share gain for our doctor detailed products indicating a robust demand, and increased efforts to improve awareness of our self-select products. We remain confident in our integrated growth strategy of a focused product portfolio where performance drives brand choice, superiority, productivity, constructive disruption, and an agile and accountable organization structure to help drive growth and value creation,”he added. Result PDF
Pharmaceuticals company Procter & Gamble Health announced Q2FY24 results: In a challenging operating environment, the company reported sales of Rs 304 crore, at par vs a year ago. The Profit After Tax (PAT) for the quarter was Rs 72 crore, down 6% vs year ago, owing to one-time items in the quarter. Excluding this one-time impact, Profit After Tax (PAT) was up by 2% vs a year ago. Milind Thatte, Managing Director, P&G; Health India, said, “This has been a challenging quarter for the Company on account of an overall slowdown in the Vitamins, Minerals and Supplements category coupled with a delayed seasonal onset. The team continued to stay resilient. With improved productivity, efficiency and continued strategic investments, we have been able to deliver a modest topline and bottom-line. We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure. We are confident that this strategy combined with our operational agility will help us navigate the mid-term and deliver balanced growth.” Result PDF
Pharmaceuticals company Procter & Gamble Health announced Q4FY23 & FY23 results: Q4FY23: Reported a sale of Rs 306.6 crore up by about 3% versus Q4FY22. The sales grew at low single digit against the headwinds of slowing down of the category in Q4FY23. The company reported a PAT of Rs 29.8 crore, a decline of 28% against Q4FY22 on account of higher material costs and one-time employee costs. FY23: The company has recorded a strong performance with sales of Rs 1,206 crore, up by 10% vs. FY22. Profit after tax (PAT) for FY23 is Rs 229 crore, up by 19% versus FY22. The board of directors has recommended a final dividend of Rs 50 per equity share, for FY23. “We continued our efforts towards brand and category development and thus delivered a strong performance in the fiscal, marked by consistent growth across all our brands. The quarter, however, witnessed a category slowdown across our portfolio. Despite these challenges, we continued our commitment to our strategy of five integrated choices: a portfolio of daily-use products where performance drives brand choice; superiority across product, package, brand communication, retail execution, and value; productivity; constructive disruption of the entire value chain; and a highly efficient and effective organization structure. We raised awareness and education among our consumers through initiatives like Neuropathy Awareness Week, wherein leading Global Health Experts converged to address the growing Public Health Concern of Peripheral Neuropathy. This also reinforced our efforts towards building an ecosystem for scientific collaboration and knowledge-sharing among healthcare professionals. We also commemorated World Health Day by launching the Pragati Utsav, an initiative to raise awareness and empower the healthcare professionals of rural hinterlands, on Vitamin B deficiency. We bolstered our go-to-market strategy and strengthened our partnerships across omni-channel stores, increasing the availability and access of our brands across online and offline platforms, thereby helping meet the needs of our consumers and customers. We launched the first-of-its-kind policies for employees, including the end-to-end support for children with special needs and a co-pay India Day Care policy, We continued to foster an environment of equal opportunities at the workplace. SEHAT, our flagship CSR program, continued to remain a priority during this fiscal year where we continued to strengthen public health through our strategic initiatives,” said Milind Thatte, Managing Director, Procter & Gamble Health. Result PDF
Pharmaceuticals firm Procter & Gamble Health announced Q3FY23 (quarter ending June) results: Total sales of Rs 316.3 crore for the quarter ended March 31, 2023, vs Rs 262.2 crore, a year ago, up by 21%. Profit After Tax (PAT) was Rs 59.2 crore, up by 16% vs a year ago. Sales for the nine-month period ending March 31, 2023, was Rs 912.8 crore vs Rs 803.2 crore a year ago. PAT for a nine-month period was Rs 199.7 crore vs Rs 151.4 crore a year ago, despite the high inflationary pressures Mr. Milind Thatte, Managing Director, P&G; Health India, said, “We continue to register a consistent growth in this quarter despite a challenging macro-economic environment. This has been made possible through our integrated growth strategies of expanded reach and improved productivity, while we continue to create awareness among our patients and consumers alike. The cornerstone of our approach continues to be our robust product line, which helps meet the rising demand for daily supplements, thereby helping us deliver the 6th consecutive quarter of strong growth. Our focus brands, Evion, Neurobion and Livogen continue to perform exceptionally well. The quarter also saw Neurobion regain its position as India’s No. 1 Nerve Care Brand, while Livogen’s exceptional performance continued behind the award winning campaign ‘Na Na Anemia’ with Diagnostic camps across the country. Under our flagship CSR Program, SEHAT, in partnership with Tata Trust’s ‘Yes! To Poshan’Program, we continued to showcase our commitment towards the cause of maternal & child health.”. “The quarter also saw us receive various prestigious recognitions. We are thankful to the CSR Summit and Awards 2023, CII, Exchange4media and Obesity International for recognizing our Corporate Social Responsibility and Consumer Awareness efforts. These recognitions have further fueled our passion and commitment to serve Indian consumers and help them live healthier lives,” he concluded. Result PDF